CA242 as a Tumor Marker in Gastrointestinal Cancer
Author Information
Author(s): O. Nilsson, C. Johansson, B. Glimelius, B. Persson, B. N0rgaard-Pedersen, A. Andren-Sandberg, L. Lindholm
Hypothesis
The CA242 assay will show better sensitivity and specificity for gastrointestinal cancers compared to existing markers.
Conclusion
The CA242 assay demonstrates higher tumor specificity and sensitivity in colorectal cancer compared to CA50 and CA19-9.
Supporting Evidence
- CA242 showed better tumor specificity than CA50 and CA19-9.
- The sensitivity of CA242 was approximately three times higher than CA50 in colorectal cancer.
- Combining CA242 with CEA significantly increased sensitivity in colorectal cancer patients.
Takeaway
CA242 is a new test that helps doctors find certain types of cancer better than older tests.
Methodology
The study developed a Delfia assay for CA242 and compared its sensitivity and specificity in colorectal and pancreatic cancer against other established markers.
Limitations
The study primarily focused on specific cancer types and may not generalize to all gastrointestinal cancers.
Participant Demographics
Included healthy subjects, patients with benign diseases, and various stages of colorectal and pancreatic cancer.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website